Medicare is entering 2026 with several significant changes that directly affect how patients pay for medications, how claims are processed, and how insurance plans handle prior authorization. Understanding these updates now can help you avoid billing errors and ensure you are getting the coverage you are entitled to.
1. Negotiated Drug Prices Take Effect Under the Inflation Reduction Act
January 1, 2026 marks one of the most consequential changes to Medicare drug pricing in decades. For the first time, Medicare has the authority to negotiate drug prices directly with manufacturers — and those negotiated prices are now in effect for ten high-cost medications.
The ten drugs with negotiated 2026 prices include widely used medications such as Eliquis (blood thinner), Jardiance (diabetes/heart failure), Xarelto (blood thinner), Januvia (diabetes), Farxiga (diabetes/heart failure), Entresto (heart failure), Enbrel (arthritis), Imbruvica (blood cancers), Stelara (immune conditions), and Fiasp/NovoLog (insulin). If you take any of these medications under Medicare Part D, your out-of-pocket cost should be significantly lower in 2026.
Auditing tip: If you are being charged the pre-negotiation price for any of these ten drugs after January 1, 2026, that is a billing error. COA Auditing can review your Part D statements to confirm your plan is applying the correct negotiated price.
2. Electronic Prior Authorization Now Required for Medicare Advantage and Part D
CMS's Interoperability and Prior Authorization Final Rule requires Medicare Advantage plans and Part D sponsors to implement electronic prior authorization (ePA) systems starting in 2026. This means prior authorization requests must be submitted and processed electronically, reducing the delays and errors that come with paper or phone-based processes.
Plans are also required to report prior authorization metrics publicly — including approval rates, denial rates, and average decision times. This transparency gives patients and auditors important data to identify plans that are improperly denying claims at above-average rates.
Auditing tip: If your Medicare Advantage plan denied a prior authorization request without a timely decision or failed to provide a specific clinical reason, you have grounds to appeal. These new transparency requirements also make it easier to build an appeal case with documented denial rate data.
3. The $2,000 Part D Out-of-Pocket Cap Is Now the New Normal
The $2,000 annual out-of-pocket cap on Part D prescription drug costs, introduced in 2025, is now fully established. In 2026, beneficiaries also have the option to spread their out-of-pocket costs evenly throughout the year through the Medicare Prescription Payment Plan (M3P) — a smoothing program that prevents large one-time drug costs from hitting all at once.
Auditing tip: If you enrolled in M3P and your monthly installments do not match your actual drug costs for the year, or if costs are being applied to your cap incorrectly, a Part D EOB review can catch these discrepancies before they become larger problems.
4. Medicare Advantage Star Ratings and Plan Changes
CMS has updated the Star Ratings methodology for 2026 Medicare Advantage plans. Measures now place greater weight on health equity, care coordination, and member experience — including how well plans handle prior authorization appeals. Beneficiaries enrolled in lower-rated plans may see reduced benefits or higher premiums in 2026.
If your Medicare Advantage plan changed its benefits, formulary, or network for 2026, it is worth reviewing your current coverage to confirm any services or medications you rely on are still covered at the same cost-sharing level. Changes to formularies frequently lead to unexpected out-of-pocket charges that can be appealed.
5. Continued Telehealth Coverage Through 2026
Medicare's expanded telehealth flexibilities remain in effect through the end of 2026. Beneficiaries can continue receiving telehealth services from home without geographic restrictions, and mental health services via telehealth are covered with reduced in-person visit requirements. Audio-only visits for patients who cannot access video technology also remain covered.
Auditing tip: Telehealth claims continue to be a common source of billing errors — particularly incorrect place-of-service codes (POS 02 vs. POS 10) and missing or incorrect modifiers. If you have had telehealth visits billed under Medicare and received unexpected cost-sharing, a claims review is warranted.
What These Changes Mean for Your Claims
Every major policy change creates a window where billing systems lag behind new rules. Plans update their systems, providers update their coding, and errors slip through. The negotiated drug pricing change alone will require Part D plans to update pricing databases for ten drugs simultaneously — and discrepancies are inevitable in the transition period.
Common issues to watch for in 2026: pre-negotiation pricing still applied to the ten IRA drugs; prior authorization denials without electronic processing or required clinical rationale; Part D out-of-pocket costs not correctly tracking toward the $2,000 cap; and telehealth claims with outdated coding.
How COA Auditing Can Help
Based in Marietta, GA and serving the greater Atlanta area, COA Auditing reviews Medicare and commercial insurance claims for errors, underpayments, and improperly applied charges. With 20 years of experience in medical coding and patient indemnity recovery, we know where billing mistakes hide — especially during Medicare policy transitions like those taking effect in 2026.
If you have questions about your Medicare bills, an EOB that doesn't look right, or a prior authorization denial you want to challenge, contact us for a free initial consultation. There is no obligation to proceed.